Clinical Trials
12
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Study Evaluating the Pharmacokinetic Profile of Novel Formulations of RHUDEX®
- Conditions
- Formulation Finding
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2012-06-21
- Lead Sponsor
- MediGene
- Target Recruit Count
- 12
- Registration Number
- NCT01500122
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- MediGene
- Target Recruit Count
- 30
- Registration Number
- NCT01490008
- Locations
- 🇩🇪
CardioSec Clinical Reasearch GmbH, Erfurt, Germany
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
- Conditions
- Genital WartsPerianal Warts
- Interventions
- Other: Green Tea Beverage with defined catechin contentDrug: Polyphenon E (Veregen) 15% ointment
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2010-09-08
- Lead Sponsor
- MediGene
- Target Recruit Count
- 43
- Registration Number
- NCT01082302
- Locations
- 🇩🇪
Charité Research Organisation, Berlin, Germany
Study Evaluating the Pharmacokinetic Profile of RhuDex® in a Tablet Formulation
- Conditions
- Pharmacokinetics
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- MediGene
- Target Recruit Count
- 12
- Registration Number
- NCT00704119
- Locations
- 🇬🇧
Charles River Clinical Services Edinburgh Ltd, Edinburgh, Scotland, United Kingdom
A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
- Conditions
- Liver CancerNeoplasm Metastasis
- Interventions
- Drug: EndoTAG®-1
- First Posted Date
- 2007-10-10
- Last Posted Date
- 2010-02-09
- Lead Sponsor
- MediGene
- Target Recruit Count
- 20
- Registration Number
- NCT00542048
- Locations
- 🇩🇪
Klinik für Internistische Onkologie in der KTB Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg, Freiburg Im Breisgau, Baden-Würtemberg, Germany
- Prev
- 1
- 2
- 3
- Next
News
Curatis Reveals Corticorelin as Active Substance in C-PTBE-01 with Billion-Dollar Market Potential
Curatis has disclosed that Corticorelin is the active substance in its C-PTBE-01 therapy for peritumoral brain edema (PTBE), with potential to reduce or eliminate steroid use in treatment.
Medigene Advances TCR-T Therapies with FDA Clearance and Strategic Partnerships
Medigene received FDA clearance for its IND application for MDG1015, a TCR-T therapy targeting NY-ESO-1/LAGE-1a, for advanced solid tumors.
FDA Clears IND for Medigene's TCR-T Therapy MDG1015 in Advanced Solid Tumors
Medigene receives FDA clearance for its Investigational New Drug (IND) application for MDG1015, a T-cell receptor engineered T-cell (TCR-T) therapy.